|
NOL10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.54369999952431E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26519999998909E-06 |
| Normal-vs-Stage2 |
2.146300E-02 |
| Normal-vs-Stage3 |
1.4891999999822E-07 |
| Normal-vs-Stage4 |
4.09270000000239E-05 |
| Stage1-vs-Stage2 |
2.495200E-01 |
| Stage1-vs-Stage3 |
1.068430E-01 |
| Stage1-vs-Stage4 |
6.404400E-01 |
| Stage2-vs-Stage3 |
3.511600E-02 |
| Stage2-vs-Stage4 |
1.994240E-01 |
| Stage3-vs-Stage4 |
4.701200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.10919999962711E-07 |
| Normal-vs-AfricanAmerican |
2.443500E-02 |
| Normal-vs-Asian |
1.882930E-03 |
| Caucasian-vs-AfricanAmerican |
3.491200E-01 |
| Caucasian-vs-Asian |
2.642600E-01 |
| AfricanAmerican-vs-Asian |
9.146600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.56624999999577E-05 |
| Normal-vs-Female |
6.84630000025166E-07 |
| Male-vs-Female |
5.324400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.84642999999651E-05 |
| Normal-vs-Age(41-60Yrs) |
4.11479999962161E-07 |
| Normal-vs-Age(61-80Yrs) |
9.51569999999569E-05 |
| Normal-vs-Age(81-100Yrs) |
2.471500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.539400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.735000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.925200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.768400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.134000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.186600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.534100E-02 |
| Classical-VS-Follicular |
4.497400E-01 |
| Classical-VS-Other |
9.327800E-02 |
| Classical-VS-Normal |
4.20720000000596E-05 |
| Tall-VS-Follicular |
3.724600E-01 |
| Tall-VS-Other |
4.953200E-01 |
| Tall-VS-Normal |
2.03209999999343E-05 |
| Follicular-VS-Other |
2.877400E-01 |
| Follicular-VS-Normal |
1.216100E-04 |
| Other-VS-Normal |
9.597500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.80269999997085E-06 |
| Normal-vs-N1 |
1.36669999761807E-08 |
| N0-vs-N1 |
2.133600E-02 |
|
|
